Invention Grant
- Patent Title: Chiral nucleic acid adjuvant
-
Application No.: US14414551Application Date: 2013-07-12
-
Publication No.: US09617547B2Publication Date: 2017-04-11
- Inventor: Takefumi Gemba
- Applicant: Shin Nippon Biomedical Laboratories, Ltd. , WaVe Life Sciences Japan
- Applicant Address: JP Kagoshima-shi JP Kagoshima-shi
- Assignee: Shin Nippon Biomedical Laboratories, Ltd.,WAVE LIFE SCIENCES JAPAN
- Current Assignee: Shin Nippon Biomedical Laboratories, Ltd.,WAVE LIFE SCIENCES JAPAN
- Current Assignee Address: JP Kagoshima-shi JP Kagoshima-shi
- Agency: Choate, Hall & Stewart—LLP
- Agent Brenda Herschbach Jarrell
- International Application: PCT/JP2013/069107 WO 20130712
- International Announcement: WO2014/010718 WO 20140116
- Main IPC: C12N15/117
- IPC: C12N15/117 ; A61K39/00 ; A61K39/39

Abstract:
ProblemThe purpose of the present invention is to provide: a stereo isomer of a novel CpG oligonucleotide, which has excellent stability; and a CpG oligonucleotide which has a capability of producing interferon-α (IFNα).SolutionThe present invention relates to an oligonucleotide which contains two to four sequences each represented by the formula 5′-X1X2CpGX3X4-3′ (formula (I)) and has a length of 14 to 32 nucleotides. In formula (I), CpG represents a non-methylated CpG residue having a phosphate skeleton modification, X1X2 represents any one of AA, AT, GA and GT, and X3X4 represents any one of TT, AT, AC and CG. The oligonucleotide has at least one phosphate skeleton modification at an S-form stereoisomer located at a site other than the CpG.
Public/Granted literature
- US20150166999A1 CHIRAL NUCLEIC ACID ADJUVANT Public/Granted day:2015-06-18
Information query
IPC分类: